Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 20OTHER 3NIH 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 29Ovarian Neoplasms 27Breast Neoplasms 27Lung Neoplasms 26Carcinoma, Ovarian Epithelial 20Fallopian Tube Neoplasms 15Adenocarcinoma of Lung 14Head and Neck Neoplasms 13Brenner Tumor 11Uterine Cervical Neoplasms 10Squamous Cell Carcinoma of Head and Neck 10Urinary Bladder Neoplasms 9Esophageal Neoplasms 9Stomach Neoplasms 8Endometrial Neoplasms 8Urethral Neoplasms 7Adenocarcinoma, Bronchiolo-Alveolar 6Sarcoma 5Prostatic Neoplasms 5Adenocarcinoma Of Esophagus 5Neurotoxicity Syndromes 4Neoplasm Metastasis 4Testicular Neoplasms 3Salivary Gland Neoplasms 3Radiation Injuries 3Esophageal Squamous Cell Carcinoma 3Breast Neoplasms, Male 3Thymoma 2Testicular Germ Cell Tumor 2Small Cell Lung Carcinoma 2

Interventions

Fluorouracil 29Leucovorin 26Oxaliplatin 25Capecitabine 16Irinotecan 14Cetuximab 10Bevacizumab 9Radiotherapy 8Panitumumab 5Folfox protocol 5Surgical Procedures, Operative 3Levamisole 3Celecoxib 3tremelimumab 2neratinib 2napabucasin 2durvalumab 2cediranib 2aflibercept 2X-Rays 2Tegafur 2Radiofrequency Ablation 2Psychiatric Rehabilitation 2Preoperative Exercise 2Octreotide 2Mitomycin 2Interviews as Topic 2Immunoglobulin G 2Folic Acid 2Floxuridine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Colorectal Neoplasms × Paclitaxel × Clear all
NCT00107250 2023-08-04

AZD2171 + Chemotherapy in Advanced NSCLC, Colorectal Cancer, or Other Cancer Suitable for Treatment With Capecitabine (Non-Small Lung Cancer Patients Closed to Enrollment as 8/9/07)

Canadian Cancer Trials Group

Phase 1 Completed
50 enrolled
GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Lung Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡